Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by mercedesmanon Feb 25, 2021 4:06pm
122 Views
Post# 32660901

RE:RE:RE:RE:Low Volume + High Share Control

RE:RE:RE:RE:Low Volume + High Share Controlwhy do you think that the company valued Dialco at only 60 cents in their December presentation?   Cuz, in the absence of general market awareness, Analyst coverage, etc. especially south of the border, they need to discount it, in order to incentize early takers to offset perceived "risk".

why do you think that the recent clinic DIMI FDA approval and recent IDE approval have been so damaging to the share price?  The market is highly inefficient for Cdn small caps off the US radar. the news wasn't damaging, it just didn't resonate where it counts, IMO

do you think that there will be more valuation integrity in the share price as Dr Kellum gets acquainted with his role?  Hopefully.  He lends major credibilty, likely has key connections, opens doors...and a few other things.
<< Previous
Bullboard Posts
Next >>